Skip to main content Skip to section navigation Skip to footer
Top
Lantern Pharma Inc.
INVESTORS
Home
Investors
Contact
About
Welcome
Mission
Partnering
Patents
A.I. Platform
Our Technology
RADR®
Collaborations
Pipeline
Overview
LP100 | LP184 | LP284 | LP300 | ADC Program
Clinical Trials
Compassionate Use
Publications
Posters
TEAM
Leadership
Board of Directors
Advisors
Lantern Careers
MEDIA
News
Press
Social Media
Newsletter
Videos
Webinars
ContactInvestors

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Media Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Media Coverage
  • Email Alerts
Sep 25, 2023 8:30am EDT

Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors

Sep 18, 2023 9:00am EDT

Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas

Aug 31, 2023 8:00am EDT

Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting

Aug 28, 2023 8:00am EDT

Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors

Aug 14, 2023 8:30am EDT

Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT

Aug 09, 2023 4:01pm EDT

Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights

Aug 02, 2023 8:00am EDT

Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET

Jul 17, 2023 8:00am EDT

Lantern Pharma to Participate and Present at Multiple Upcoming Conferences

Jun 26, 2023 8:30am EDT

Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas

Jun 12, 2023 8:30am EDT

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 14
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed

Join our Mailing List to get the latest Lantern news, sent right to your inbox

Sign me up for:

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.
Never spam. Unsubscribe anytime.
Tweets by LanternPharma
View on Webflow
About
Welcome
Mission
Partnering
Patents
A.I. Platform
Our Technology
RADR®
Collaborations
Pipeline
Overview
LP100 | LP184 | LP284 | LP300 | ADC Program
Clinical Trials
Compassionate Use
Publications
Posters
TEAM
Leadership
Board Of Directors
Advisors
Lantern Careers
MEDIA
News
Press
Social Media
Newsletter
Videos
Webinars
Investors
Contact
TwitterYoutubeLinkedin
©Copyright 2023 Lantern Pharma Inc.
Privacy Policy